FRI0475 TITLE: LUMBAR SPINE AND PROXIMAL FEMUR OSTEOPOROSIS DIAGNOSIS: REMS TECHNOLOGY IN A MULTICENTER CLINICAL STUDY

Autor: Ombretta Viapiana, G. Arioli, Marco Matucci-Cerinic, Monica Manfedini, Carla Caffarelli, Ranuccio Nuti, Stefano Gonnelli, G. Girasole, Luisella Cianferotti, Maurizio Muratore, Marco Di Paola, Maria Luisa Brandi, Giovanni Adami, Francesco Conversano, Loredana Cavalli, Davide Gatti, L. Quarta, Gerolamo Bianchi, Andrea Giusti, Paola Pisani
Rok vydání: 2019
Předmět:
Zdroj: Osteoporosis.
DOI: 10.1136/annrheumdis-2019-eular.6256
Popis: Background To date numerous quantitative methods to diagnose osteoporosis at peripheral sites have been developed. REMS (Radiofrequency Echographic Multi Spectrometry) is a non-ionizing instrument used to quantitatively evaluate bone mineral density at lumbar spine and femoral neck sites [1]. Objectives To assess the accuracy of REMS in osteoporosis diagnosis at axial sites (lumbar spine and hip) compared with the gold standard, Dual-energy X-ray absorptiometry (DXA). Methods We enrolled patients aged from 50 to 75 years and perfomed a total of 1,699 and 1,794 lumbar spine and proximal femur scans with REMS and DXA. A quality checks on DXA and REMS acquired data were performed through direct examination of scans by experienced operators. We investigated the agreement between the two techniques calculating: Pearson`s correlation coefficient (r), Standard Error of the Estimate (SEE) and efficiency (sensitivity and specificity) in identifying osteoporotic individuals (i.e. T-score ≤ -2.5). Results We found a good linear correlation between REMS and DXA BMD estimation, Pearson coefficient r=0.938 for lumbar spine and r=0.933 for proximal femur (p Conclusion REMS exhibited a high sensitivity and specificity in identifying osteoporotic patients at lumbar spine or proximal femur sites compared with gold-standard DXA. REMS accurately diagnosed osteoporotic patients in clinical routine, at both lumbar spine and proximal femur sites, without using ionizing radiation. References [1] Di Paola M, Gatti D, Viapiana O, et al. Osteoporos Int, 2018 Disclosure of Interests Giovanni Adami: None declared, Giovanni Arioli: None declared, Gerolamo Bianchi: None declared, Maria Luisa Brandi: None declared, Carla Caffarelli: None declared, Loredana Cavalli: None declared, Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS; MSD, Janssen, Luisella Cianferotti Speakers bureau: Abiogen Pharma, Bruno Farmaceutici, Shire, Francesco Conversano Shareholder of: Francesco Conversano own stocks of Echolight Spa, Marco Di Paola: None declared, Davide Gatti Speakers bureau: Abiogen, Amgen, Janssen-Cilag, Mundipharma, Pfeizer, Giuseppe Girasole: None declared, Andrea Giusti: None declared, Stefano Gonnelli: None declared, Monica Manfedini: None declared, Maurizio Muratore: None declared, Ranuccio Nuti: None declared, Paola Pisani: None declared, Laura Quarta: None declared, Ombretta Viapiana Speakers bureau: Novartis, Abbvie, Eli-Lilly, Sanofi Genzyme
Databáze: OpenAIRE